| ［1］ |
中华医学会皮肤性病学分会银屑病专业委员会. 中国银屑病诊疗指南（2018完整版）［J］. 中华皮肤科杂志, 2019,52（10）:667⁃710. doi: 10.35541/cjd.20190847.
|
| ［2］ |
Shobeiri SS, Khorrami M, Sankian M. Plaque⁃type psoriasis inhibitors［J］. Int Immunopharmacol, 2021,101（Pt B）:108326. doi: 10.1016/j.intimp.2021.108326.
|
| ［3］ |
Krueger JG, McInnes IB, Blauvelt A. Tyrosine kinase 2 and Janus kinase⁃signal transducer and activator of transcription signaling and inhibition in plaque psoriasis［J］. J Am Acad Dermatol, 2022,86（1）:148⁃157. doi: 10.1016/j.jaad.2021.06.869.
|
| ［4］ |
Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review［J］. JAMA, 2020,323（19）:1945⁃1960. doi: 10.1001/jama.2020.4006.
|
| ［5］ |
Zhang LJ. Type1 interferons potential initiating factors linking skin wounds with psoriasis pathogenesis［J］. Front Immunol, 2019,10:1440. doi: 10.3389/fimmu.2019.01440.
|
| ［6］ |
Afonina IS, Van Nuffel E, Beyaert R. Immune responses and therapeutic options in psoriasis［J］. Cell Mol Life Sci, 2021,78（6）:2709⁃2727. doi: 10.1007/s00018⁃020⁃03726⁃1.
|
| ［7］ |
Salas A, Hernandez⁃Rocha C, Duijvestein M, et al. JAK⁃STAT pathway targeting for the treatment of inflammatory bowel disease［J］. Nat Rev Gastroenterol Hepatol, 2020,17（6）:323⁃337. doi: 10.1038/s41575⁃020⁃0273⁃0.
|
| ［8］ |
Gotthardt D, Trifinopoulos J, Sexl V, et al. JAK/STAT cytokine signaling at the crossroad of NK cell development and maturation［J］. Front Immunol, 2019,10:2590. doi: 10.3389/fimmu.2019. 02590.
|
| ［9］ |
Ciobanu DA, Poenariu IS, Crînguș LI, et al. JAK/STAT pathway in pathology of rheumatoid arthritis（review）［J］. Exp Ther Med, 2020,20（4）:3498⁃3503. doi: 10.3892/etm.2020.8982.
|
| ［10］ |
Hu X, Li J, Fu M, et al. The JAK/STAT signaling pathway: from bench to clinic［J］. Signal Transduct Target Ther, 2021,6（1）:402. doi: 10.1038/s41392⁃021⁃00791⁃1.
|
| ［11］ |
Pan Y, Mader MM. Principles of kinase allosteric inhibition and pocket validation［J］. J Med Chem, 2022,65（7）:5288⁃5299. doi: 10.1021/acs.jmedchem.2c00073.
|
| ［12］ |
Wrobleski ST, Moslin R, Lin S, et al. Highly selective inhibition of tyrosine kinase 2（TYK2） for the treatment of autoimmune diseases: discovery of the allosteric inhibitor BMS⁃986165［J］. J Med Chem, 2019,62（20）:8973⁃8995. doi: 10.1021/acs.jmedchem. 9b00444.
|
| ［13］ |
T Virtanen A, Haikarainen T, Raivola J, et al. Selective JAKinibs: prospects in inflammatory and autoimmune diseases［J］. BioDrugs, 2019,33（1）:15⁃32. doi: 10.1007/s40259⁃019⁃00333⁃w.
|
| ［14］ |
Blanque R, Shoji K, Jans M, et al. Pharmacological characterization of GLPG3667, a selective TYK2 inhibitor for treatment of inflammatory diseases［J］. Arthritis Rheumatol, 2021, 73（suppl 9）. doi: 10.1002/art.41966.
|
| ［15］ |
Attwood MM, Fabbro D, Sokolov AV, et al. Trends in kinase drug discovery: targets, indications and inhibitor design［J］. Nat Rev Drug Discov, 2021,20（11）:839⁃861. doi: 10.1038/s41573⁃021⁃00252⁃y.
|
| ［16］ |
Lu X, Smaill JB, Ding K. New promise and opportunities for allosteric kinase inhibitors［J］. Angew Chem Int Ed Engl, 2020,59（33）:13764⁃13776. doi: 10.1002/anie.201914525.
|
| ［17］ |
Burke JR, Cheng L, Gillooly KM, et al. Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain［J］. Sci Transl Med, 2019,11（502）:eaaw1736. doi: 10.1126/scitranslmed.aaw1736.
|
| ［18］ |
Leit S. Discovery of NDI⁃034858, a highly potent and selective TYK2⁃JH2 inhibitor for the treatment of autoimmune diseases, through structure⁃based drug design, ACS Fall 2022 ⁃ Sessions Final［EB/OL］.（2022⁃08⁃24）［2022⁃10⁃09］. https://acs.digitellinc.com/acs/sessions/519714/view.
|
| ［19］ |
Chimalakonda A, Burke J, Cheng L, et al. Selectivity profile of the tyrosine kinase 2 inhibitor deucravacitinib compared with Janus kinase 1/2/3 inhibitors［J］. Dermatol Ther（Heidelb）, 2021,11（5）:1763⁃1776. doi: 10.1007/s13555⁃021⁃00596⁃8.
|
| ［20］ |
Papp KA, Menter MA, Abe M, et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Results from two randomized, placebo⁃controlled, phaseⅢ trials［J］. Br J Dermatol, 2015,173（4）:949⁃961. doi: 10.1111/bjd. 14018.
|
| ［21］ |
Papp KA, Menter MA, Raman M, et al. A randomized phase 2b trial of baricitinib, an oral Janus kinase（JAK） 1/JAK2 inhibitor, in patients with moderate⁃to⁃severe psoriasis［J］. Br J Dermatol, 2016,174（6）:1266⁃1276. doi: 10.1111/bjd.14403.
|
| ［22］ |
Tehlirian C, Singh RSP, Pradhan V, et al. Oral tyrosine kinase 2 inhibitor PF⁃06826647 demonstrates efficacy and an acceptable safety profile in participants with moderate⁃to⁃severe plaque psoriasis in a phase 2b, randomized, double⁃blind, placebo⁃controlled study［J］. J Am Acad Dermatol, 2022,87（2）:333⁃342. doi: 10.1016/j.jaad.2022.03.059.
|
| ［23］ |
Forman SB, Pariser DM, Poulin Y, et al. TYK2/JAK1 inhibitor PF⁃06700841 in patients with plaque psoriasis: PhaseⅡa, randomized, double⁃blind, placebo⁃controlled trial［J］. J Invest Dermatol, 2020,140（12）:2359⁃2370.e5. doi: 10.1016/j.jid.2020. 03.962.
|
| ［24］ |
Armstrong AW, Gooderham M, Warren RB, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52⁃week, randomized, double⁃blinded, placebo⁃controlled phase 3 POETYK PSO⁃1 trial［J］. J Am Acad Dermatol, 2023,88（1）:29⁃39. doi: 10.1016/j.jaad.2022.07.002.
|
| ［25］ |
Strober B, Thaçi D, Sofen H, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52⁃week, randomized, double⁃blinded, phase 3 Program for evaluation of TYK2 inhibitor psoriasis second trial［J］. J Am Acad Dermatol, 2023,88（1）:40⁃51. doi: 10.1016/j.jaad.2022.08.061.
|
| ［26］ |
Gadina M, Chisolm DA, Philips RL, et al. Translating JAKs to jakinibs［J］. J Immunol, 2020,204（8）:2011⁃2020. doi: 10.4049/jimmunol.1901477.
|
| ［27］ |
Choy EH. Clinical significance of janus kinase inhibitor selectivity［J］. Rheumatology（Oxford）, 2019,58（6）:953⁃962. doi: 10.1093/rheumatology/key339.
|
| ［28］ |
Zhang J, Ding Y, Li H, et al. Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in Asian patients with moderate⁃to⁃severe plaque psoriasis: findings from the phase 3 POETYK PSO⁃3 trial［J］//European Academy of Dermatology and Venereology. Proceedings from the 31th EADV Congrass［C］. Milan, Italy, 2022: Abstract D3T01.1B.
|
| ［29］ |
Warren RB, Sofen H, Imafuku S, et al. Deucravacitinib long⁃term efficacy and safety in plaque psoriasis: 2⁃year results from the phase 3 POETYK PSO program［J］. Ann Rheum Dis, 2022,81（Suppl 1）:841. doi: 10.1136/annrheumdis⁃2022⁃eular.2445.
|
| ［30］ |
McElwee JJ, Garcet S, Li X, et al. Analysis of histologic and molecular improvement in moderate⁃to⁃severe psoriasis: results from a phase 1b trial of the novel allosteric Tyk2 inhibitor NTX⁃973［J］. J Am Acad Dermatol, 2022,87（3_suppl）:AB139. doi:10.1016/j.jaad.2022.06.590.
|
| ［31］ |
Armstrong A, Lynde C, Forman S, et al. Efficacy and safety results from the randomized, double⁃blind, placebo⁃controlled phase 2b trial of TYK2 inhibitor NDI⁃034858 in moderate⁃to⁃severe psoriasis［J］. American Academy of Dermatology. Proceedings of the 2023 Annual Meeting of American Academy of Dermatology［C］. New Orleans, LA, United States, 2023: Session S025.
|
| ［32］ |
Banfield C, Scaramozza M, Zhang W, et al. The safety, tolerability, pharmacokinetics, and pharmacodynamics of a TYK2/JAK1 inhibitor（PF⁃06700841） in healthy subjects and patients with plaque psoriasis［J］. J Clin Pharmacol, 2018,58（4）:434⁃447. doi: 10.1002/jcph.1046.
|
| ［33］ |
Thaçi D, Molnar J, Timmis H, et al. Phase 1b randomized, double⁃blind, placebo⁃controlled study evaluating the safety, tolerability, and efficacy of GLPG3667 in patients with moderate⁃to⁃severe plaque psoriasis［J］. J Am Acad Dermatol, 2022,87（3_suppl）:AB92. doi: 10.1016/j.jaad.2022.06.402.
|
